Diabetes and Endocrinology

Episodes 1-5 of 5

• • 

    

    Michael Miller, MD, FACC, FAHA, FNLA

    Peer

  • 

    

    Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC

    Peer

  2

  

  RestartResume

  Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA

  RestartResume

  Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA

  0.25 credits

  Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Ac...

  0.25 credits

• • 

    

    Eliot Brinton, MD, FAHA, FNLA

    Peer

  • 

    

    Erin D. Michos, MD, MHS, FACC, FAHA, FASE

    Peer

  21

  CME/CE Broadcast Replay

  

  RestartResume

  The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue

  RestartResume

  The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue

  0.75 credits

  The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert D...

  0.75 credits

• • 

    

    Eliot Brinton, MD, FAHA, FNLA

    Peer

  • 

    

    Erin D. Michos, MD, MHS, FACC, FAHA, FASE

    Peer

  10

  

  0.25 credits

  Prevention of ASCVD in Women Through Lipid Management in the New Era

  0.25 credits

• • 

    

    Michel Farnier, MD, PhD

    Peer

  • 

    

    Børge G. Nordestgaard, MD, DMSc

    Peer

  8

  

  RestartResume

  Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)

  RestartResume

  Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)

  0.75 credits

  Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl ...

  0.75 credits

• • 

    

    Christopher P. Cannon, MD

    Peer

  • 

    

    Samuel Dagogo-Jack, MD, DSc

    Peer

  12

  

  RestartResume

  Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

  RestartResume

  Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

  0.25 credits

  Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients wit...

  0.25 credits